{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:59:58Z","timestamp":1790423998141,"version":"4.1.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI105147, 2R56NS041858-15A1, 1R01NS097195-01, R03 NS094071-01"],"award-info":[{"award-number":["R01 AI105147, 2R56NS041858-15A1, 1R01NS097195-01, R03 NS094071-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00722","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:18:37Z","timestamp":1523492317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":104,"title":["Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika Virus Through Direct Inactivation and Interferon Pathway"],"prefix":"10.3389","volume":"9","author":[{"given":"Miao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hainan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangshun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2636","DOI":"10.1371\/journal.pntd.0002636","article-title":"Molecular evolution of Zika virus during its emergence in the 20(th) century","volume":"8","author":"Faye","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-016-0660-0","article-title":"The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact","volume":"14","author":"Boeuf","year":"2016","journal-title":"BMC Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(16)00651-6","article-title":"Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study","volume":"387","author":"Cauchemez","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2471\/BLT.16.176990","article-title":"Defining the syndrome associated with congenital Zika virus infection","volume":"94","author":"Costello","year":"2016","journal-title":"Bull World Health Organ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika virus associated with microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects \u2013 reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","volume-title":"Zika Virus Country Classification Scheme: Interim Guidance","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20720","DOI":"10.2807\/1560-7917.ES2014.19.9.20720","article-title":"Zika virus infection complicated by Guillain-Barre syndrome \u2013 case report, French Polynesia, December 2013","volume":"9","author":"Oehler","year":"2014","journal-title":"Euro Surveill"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/S0140-6736(16)30058-7","article-title":"Guillain-Barre syndrome associated with Zika virus infection","volume":"387","author":"Brasil","year":"2016","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/QCO.0000000000000301","article-title":"Zika virus infection: epidemiology, clinical manifestations and diagnosis","volume":"29","author":"Calvet","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"B12","volume-title":"Epidemiological Update: Neurological Syndrome, Congenital Anomalies and Zika Virus Infection","year":"2016"},{"key":"B13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","article-title":"Antimicrobial peptides of multicellular organisms","volume":"415","author":"Zasloff","year":"2002","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ijantimicag.2004.09.005","article-title":"Antimicrobial peptides: premises and promises","volume":"24","author":"Reddy","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"B15","doi-asserted-by":"publisher","first-page":"D1087","DOI":"10.1093\/nar\/gkv1278","article-title":"APD3: the antimicrobial peptide database as a tool for research and education","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1007\/s00018-017-2604-z","article-title":"Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects","volume":"74","author":"Baxter","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/ph7050545","article-title":"Human antimicrobial peptides and proteins","volume":"7","author":"Wang","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1749-6632.1997.tb46244.x","article-title":"The cathelicidin family of antimicrobial peptide precursors: a component of the oxygen-independent defense mechanisms of neutrophils","volume":"832","author":"Zanetti","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1432-1033.1996.0325z.x","article-title":"The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes","volume":"238","author":"Gudmundsson","year":"1996","journal-title":"Eur J Biochem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1189\/jlb.0704380","article-title":"Impact of LL-37 on anti-infective immunity","volume":"77","author":"Bowdish","year":"2005","journal-title":"J Leukoc Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.bbamem.2006.03.030","article-title":"LL-37, the only human member of the cathelicidin family of antimicrobial peptides","volume":"1758","author":"Durr","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MOH.0b013e32831ac517","article-title":"The roles of cathelicidin LL-37 in immune defences and novel clinical applications","volume":"16","author":"Nijnik","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00005-009-0057-2","article-title":"Cathelicidin LL-37: a multitask antimicrobial peptide","volume":"58","author":"Bucki","year":"2010","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cellimm.2012.11.009","article-title":"A comprehensive summary of LL-37, the factotum human cathelicidin peptide","volume":"280","author":"Vandamme","year":"2012","journal-title":"Cell Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0165-5728(99)00049-1","article-title":"Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia","volume":"98","author":"Zheng","year":"1999","journal-title":"J Neuroimmunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0165-5728(03)00222-4","article-title":"HIV-1 and IL-1 beta regulate Fas ligand expression in human astrocytes through the NF-kappa B pathway","volume":"141","author":"Ghorpade","year":"2003","journal-title":"J Neuroimmunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-018-0017-2","article-title":"Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869","volume":"4","author":"Huang","year":"2018","journal-title":"Cell Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1021\/ja0584875","article-title":"Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region","volume":"128","author":"Li","year":"2006","journal-title":"J Am Chem Soc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"32637","DOI":"10.1074\/jbc.M805533200","article-title":"Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles","volume":"283","author":"Wang","year":"2008","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ijantimicag.2012.02.003","article-title":"Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300","volume":"39","author":"Menousek","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"B31","doi-asserted-by":"crossref","first-page":"1700259","DOI":"10.1002\/adbi.201700259","article-title":"Amino acid composition determines peptide activity spectrum and hot spot-based design of merecidin","volume":"2","author":"Wang","year":"2018","journal-title":"Adv Biosyst"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1128\/AAC.00452-08","article-title":"Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins","volume":"52","author":"Wang","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1021\/cb500475y","article-title":"Transformation of human cathelicidin LL-37 into selective, stable, and potent antimicrobial compounds","volume":"9","author":"Wang","year":"2014","journal-title":"ACS Chem Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"28375","DOI":"10.1074\/jbc.271.45.28375","article-title":"Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities","volume":"271","author":"Skerlavaj","year":"1996","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/CIRCRESAHA.116.309866","article-title":"AXL-mediated productive infection of human endothelial cells by Zika virus","volume":"119","author":"Liu","year":"2016","journal-title":"Circ Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e5397","DOI":"10.1371\/journal.pone.0005397","article-title":"Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages","volume":"4","author":"Huang","year":"2009","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.4049\/jimmunol.172.3.1763","article-title":"Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum","volume":"172","author":"Howell","year":"2004","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pd.4880","article-title":"Imaging of congenital Zika virus infection: the route to identification of prognostic factors","volume":"36","author":"Vouga","year":"2016","journal-title":"Prenat Diagn"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMc1609015","article-title":"Zika virus and the Guillain-Barre syndrome \u2013 case series from seven countries","volume":"375","author":"Dos Santos","year":"2016","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1605564","article-title":"Guillain-Barre syndrome associated with Zika virus infection in Colombia","volume":"375","author":"Parra","year":"2016","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.celrep.2016.05.074","article-title":"The IFITMs inhibit Zika virus replication","volume":"15","author":"Savidis","year":"2016","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models","volume":"23","author":"Shan","year":"2017","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(17)31450-2","article-title":"An update on Zika virus infection","volume":"390","author":"Baud","year":"2017","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.05637-11","article-title":"Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL-37","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s100960050457","article-title":"Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides","volume":"19","author":"Yasin","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.peptides.2003.07.025","article-title":"In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs","volume":"24","author":"Benincasa","year":"2003","journal-title":"Peptides"},{"key":"B51","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijantimicag.2003.07.022","article-title":"Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus","volume":"23","author":"Albiol Matanic","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"B52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jmv.2134","article-title":"In vitro antiviral activity of dermaseptins against herpes simplex virus type 1","volume":"66","author":"Belaid","year":"2002","journal-title":"J Med Virol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.virol.2005.02.002","article-title":"The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro","volume":"334","author":"Lorin","year":"2005","journal-title":"Virology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0124706","DOI":"10.1371\/journal.pone.0124706","article-title":"Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses","volume":"10","author":"Tripathi","year":"2015","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e25333","DOI":"10.1371\/journal.pone.0025333","article-title":"Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37","volume":"6","author":"Barlow","year":"2011","journal-title":"PLoS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e73659","DOI":"10.1371\/journal.pone.0073659","article-title":"The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus","volume":"8","author":"Currie","year":"2013","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1159\/000354465","article-title":"Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo","volume":"32","author":"Hou","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ebiom.2016.11.017","article-title":"Zika virus infection in dexamethasone-immunosuppressed mice demonstrating disseminated infection with multi-organ involvement including orchitis effectively treated by recombinant type I interferons","volume":"14","author":"Chan","year":"2016","journal-title":"EBioMedicine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","article-title":"A mouse model of Zika virus pathogenesis","volume":"19","author":"Lazear","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e01970","DOI":"10.1128\/JVI.01970-16","article-title":"The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling","volume":"91","author":"Best","year":"2017","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.peptides.2010.07.028","article-title":"Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes","volume":"258","author":"Gazit","year":"1996","journal-title":"J Mol Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1128\/AAC.01448-09","article-title":"Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"B65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0004695","DOI":"10.1371\/journal.pntd.0004695","article-title":"The viral polymerase inhibitor 7-deaza-2\u2019-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model","volume":"10","author":"Zmurko","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2016.11.018","article-title":"Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay","volume":"138","author":"Adcock","year":"2017","journal-title":"Antiviral Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.antiviral.2016.11.015","article-title":"Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus","volume":"137","author":"Balasubramanian","year":"2017","journal-title":"Antiviral Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.immuni.2017.02.005","article-title":"Prospects for a Zika virus vaccine","volume":"46","author":"Barouch","year":"2017","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"15743","DOI":"10.1038\/ncomms15743","article-title":"DNA vaccination protects mice against Zika virus-induced damage to the testes","volume":"8","author":"Griffin","year":"2017","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2016.12.016","article-title":"Identification of novel small molecule inhibitors against NS2B\/NS3 serine protease from Zika virus","volume":"139","author":"Lee","year":"2017","journal-title":"Antiviral Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","article-title":"Nucleoside modified mRNA vaccines for infectious diseases","volume":"1499","author":"Pardi","year":"2017","journal-title":"Methods Mol Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:18:43Z","timestamp":1523492323000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2018.00722"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00722","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"article-number":"722"}}